Cam Gallagher - Mar 24, 2025 Form 4 Insider Report for Opus Genetics, Inc. (IRD)

Role
Director
Signature
/s/ Sharon Goldbach, by Power of Attorney
Stock symbol
IRD
Transactions as of
Mar 24, 2025
Transactions value $
$0
Form type
4
Date filed
3/26/2025, 04:08 PM
Previous filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRD Common Stock Award +784K +1017.97% 861K Mar 24, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRD Warrants (right to buy) Award +784K 784K Mar 24, 2025 Common Stock 784K $1.15 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275.
F2 These warrants are immediately exercisable and may be called by the Issuer at any time starting with 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's common stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.